Jan 12, 2021 / 01:20PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan. And it's my pleasure to be hosting a fireside chat with Eli Lilly's Chairman and CEO, Dave Ricks, today.
Dave, thanks for joining us. I know you always bring some great news to the conference, and certainly, the Alzheimer's update yesterday really kicked off the conference on a positive foot. I thought maybe just to open up, if you want to just make some general comments around your priorities for Lilly in 2021. Obviously, a lot of topics we can dig into from there but make some opening comments, and we'll go from there.
David A. Ricks - Eli Lilly and Company - Chairman, CEO & President
Absolutely. Well, thanks for having us, Chris, and look forward to talking about Alzheimer's later maybe. But 2020 was a kind of remarkable year in a lot of ways, and it sets up what we're focused on in '21, which is -- the first thing is we're in the middle of a strong growth period for the company, double-digit volume growth
Eli Lilly and Co at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers